About me
Sarah Demmon, M.S., is Vice President at Eli Lilly and Company. With 28 years in biopharmaceutical development, she specializes in late phase development and commercialization of fusion proteins and monoclonal antibodies. She started as an analytical chemist developing methods for proteins and antibodies and has played a key role in Lilly’s growth in biotech control strategy. Sarah holds a B.S. in Chemistry from Butler University and an M.S. from Purdue University.
